Live Breaking News & Updates on Esmo Breast

Administration of trilaciclib followed by sacituzumab govitecan showed early signals of efficacy and may reduce the incidence of adverse effects in heavily pretreated patients with unresectable locally advanced or metastatic triple-negative breast cancer, according to preliminary results from a phase 2 study. ....

United States , Lasika Seneviratne , Breast Cancer Annual Congress , Los Angeles Cancer Network In , Esmo Breast Cancer Annual Congress , Los Angeles Cancer Network , Los Angeles , African American , Cancer Annual Congress , Esmo Breast , Trilaciclib Followed By Sacituzumab Govitecan , Incidence Of Adverse Effects In Heavily Pretreated Patients With Unresectable Locally Advanced Or Metastatic Triple Negative Breast Cancer ,